IRLAB Therapeutics
Develops novel treatments for Parkinson's disease and other CNS disorders.
IRLAB | ST
Overview
Corporate Details
- ISIN(s):
- SE0012675361 (+1 more)
- LEI:
- 549300JAT34LHEI0DH60
- Country:
- Sweden
- Address:
- Arvid Wallgrens backe 20, 413 46 Göteborg
- Website:
- https://irlab.se/
- Sector:
- Manufacturing
Description
IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-21 14:55 |
IRLAB meddelar att styrelseledamot lämnar bolagets styrelse
|
Swedish | PDF • 38.2 KB | ||
| 2023-02-21 14:55 |
IRLAB reports that board member leaves the company’s Board
|
English | PDF • 37.8 KB | ||
| 2023-02-20 17:45 |
IRLAB byter vd och utser ny styrelseordförande
|
Swedish | PDF • 50.8 KB | ||
| 2023-02-20 17:45 |
IRLAB changes CEO and appoints new Chairman
|
English | PDF • 51.3 KB | ||
| 2023-01-17 21:15 |
IRLAB announces top-line results from Phase IIb trial of mesdopetam (IRL790) in…
|
English | PDF • 61.2 KB | ||
| 2023-01-17 21:15 |
IRLAB rapporterar top-line resultat från Fas IIb-studien med mesdopetam (IRL790…
|
Swedish | PDF • 63.2 KB | ||
| 2022-11-15 07:00 |
Nomination committee in IRLAB appointed ahead of annual general meeting 2023
|
English | PDF • 39.8 KB | ||
| 2022-11-15 07:00 |
Valberedningen utsedd inför IRLAB:s årsstämma 2023
|
Swedish | PDF • 40.4 KB | ||
| 2022-11-09 07:00 | Swedish | PDF • 1.1 MB | |||
| 2022-11-09 07:00 | English | PDF • 1.1 MB | |||
| 2022-08-24 07:00 | Swedish | PDF • 388.7 KB | |||
| 2022-08-24 07:00 | English | PDF • 376.5 KB | |||
| 2022-08-01 16:10 |
Changed number of shares and votes in IRLAB Therapeutics AB
|
English | PDF • 46.7 KB | ||
| 2022-08-01 16:10 |
Förändrat antal aktier och röster i IRLAB Therapeutics AB
|
Swedish | PDF • 47.7 KB | ||
| 2022-07-11 07:00 |
IRLAB expands Phase IIb/III PD-LIDs study with mesdopetam to support Phase III …
|
English | PDF • 43.7 KB |
Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IRLAB Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-05 | Kristina Torfgård | Other | Buy | 9,000 | 140,850.00 SEK |
| 2024-08-05 | Kristina Torfgård | Other | Buy | 4,500 | 70,875.00 SEK |
| 2024-05-14 | Gunnar Olof Olsson | Other | Buy | 2,000 | 31,000.00 SEK |
| 2024-05-10 | Daniel Johnsson | Other | Buy | 20,000 | 259,680.00 SEK |
| 2023-04-03 | Joakim Tedroff | Other | Buy | 51,430 | 2,038,685.20 SEK |
| 2022-09-01 | Richard Godfrey | Other | Buy | 5,000 | 174,457.00 SEK |
| 2022-08-30 | Viktor Siewertz | Other | Buy | 40 | 1,420.00 SEK |
| 2022-08-29 | Viktor Siewertz | Other | Sell | 40 | 1,408.00 SEK |
| 2022-07-15 | Joakim Tedroff | Other | Other | 84,148 | N/A |
| 2022-05-31 | Viktor Siewertz | Other | Buy | 4,500 | 170,370.00 SEK |
Peer Companies
